Leuprone 3-Monatsdepot

Leuprorelin, the active ingredient in Leuprone 3-Monatsdepot, is a GnRH agonist presented as a depot injection for subcutaneous use. It is used in the management of hormone‑dependent conditions such as prostate cancer, endometriosis, uterine fibroids, precocious puberty and as adjuvant therapy in breast cancer.

GNH USA supplies Leuprone 3-Monatsdepot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leuprorelin is employed in hormone‑dependent disease pathways to suppress sex hormone production. - Prostate cancer: reduces testosterone levels to slow tumor growth. - Endometriosis: lowers estrogen to alleviate pelvic pain and lesion progression. - Uterine fibroids: decreases estrogen to shrink fibroid size and reduce bleeding. - Precocious puberty: suppresses gonadotropin release to delay early sexual development. - Breast cancer (adjuvant therapy): lowers estrogen to reduce risk of recurrence.

Leuprorelin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hot flashes: transient sweating and warmth. - Injection site reactions: pain, erythema or swelling. - Headache: mild to moderate intensity. - Fatigue: general tiredness. - Decreased libido: reduced sexual desire.

Serious or Rare Side Effects: - Cardiovascular events: hypertension or thromboembolic episodes. - Bone mineral density loss: increased risk of osteoporosis. - Severe allergic reaction: anaphylaxis or angioedema. - Liver function abnormalities: elevated transaminases. - Pituitary apoplexy: rare hemorrhage within the gland.

When prescribing Leuprorelin, clinicians should consider several safety and handling precautions. - Cardiovascular assessment: evaluate history of hypertension, thromboembolism or heart disease. - Bone health monitoring: assess baseline bone mineral density and consider supplementation. - Hormone level checks: monitor testosterone or estrogen levels during therapy. - Diabetes management: watch for glucose intolerance or worsening diabetes. - Pregnancy and lactation: avoid use in women who are pregnant or may become pregnant; safety not established. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Leuprorelin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antidiabetic agents: may worsen glucose control; monitor blood sugar closely. - Hormone replacement therapy: concurrent estrogen or testosterone can counteract suppression.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors/inducers: may alter metabolism of concomitant drugs. - Anticoagulants: potential increased bleeding risk due to hormonal effects. - Steroids: may affect bone density when combined with GnRH agonist.